Selective estrogen receptor downregulators (SERDs)

systematic review meta-analysis network meta-analysis

Select advanced breast cancer (metastatic) All type of patientuncoded clinical condition ***       fulvestrant + anastrozolefulvestrant alonefulvestrant high dose alone fulvestrant       first line of endocrine therapyHER-2 negativeHR positivepostmenopausalpreviously treated with endocrine therapy

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression (Time to progression TTP) (13)progression or death (progression free survival PFS) (6)death (overall survival) (4)objective response (ORR) (4) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression (Time to progression TTP)	progression or death (progression free survival PFS)
advanced breast cancer (metastatic)
fulvestrant
GEICAM/2006-10    NCT	fulvestrant + anastrozole	anastrozole		HER-2 negative HR positive postmenopausal	Risk of bias	-
FACT (Bergh), 2012      NCT	fulvestrant + anastrozole	anastrozole		first line of endocrine therapy HR positive postmenopausal		negative
Mehta(SWOG-S0226), 2012      NCT	fulvestrant + anastrozole	anastrozole		HR positive		suggesting
Xu et al., 2011      NCT	fulvestrant 250mg	anastrozole		HR positive postmenopausal	Low risk of bias	-
0021 (Osborne), 2002      NCT	fulvestrant 250mg	anastrozole		postmenopausal	Low risk of bias	negative
0020 (Howell), 2002	fulvestrant 250mg	anastrozole			Risk of bias	negative
FIRST (Robertson), 2010    NCT	fulvestrant 500mg	anastrozole		first line of endocrine therapy postmenopausal		suggesting
9238UK/0005 (fluvestrant alone)    NCT	fluvestrant 250mg	exemestane		postmenopausal previously treated with endocrine therapy	Low risk of bias	-
SoFEa (Johnston) fluvestrant alone, 2012      NCT	fluvestrant 250mg	exemestane		postmenopausal previously treated with endocrine therapy		-
9238UK/0005 (combination)    NCT	fulvestrant + anastrozole	exemestane		postmenopausal previously treated with endocrine therapy	Low risk of bias	-
SoFEa (Johnston) combination, 2012      NCT	fulvestrant + anastrozole	exemestane		HR positive postmenopausal previously treated with endocrine therapy		negative
EFECT (Chia)    NCT	fulvestrant 250mg	exemestane		HR positive postmenopausal	Low risk of bias	negative
D6997L00021    NCT	fulvestrant 500mg	fulvestrant 250mg		HR positive previously treated with endocrine therapy	Low risk of bias	-
CONFIRM (Di Leo), 2010      NCT	fulvestrant 500mg	fulvestrant 250mg		HR positive previously treated with endocrine therapy	Low risk of bias	-
FINDER 1 (Ohno), 2010	fulvestrant 500mg	fulvestrant 250mg		postmenopausal		-
FINDER 2, 2010      NCT	fulvestrant 500mg	fulvestrant 250mg		postmenopausal previously treated with endocrine therapy	Exploratory	-
9238IL/0025    NCT	fulvestrant 250mg	tamoxifen		first line of endocrine therapy	Low risk of bias	-
0025 (Howell), 2004	fulvestrant 250mg	tamoxifen		previously treated with endocrine therapy	Low risk of bias	negative